Ovarian cancer 'game changer' drug which holds back disease's return gets first NHS fund approval Thousands of women could benefit from a “game changing” ovarian cancer drug which can prevent the disease recurring for as much as a year and a half after it was approved for NHS use.
As many as 850 women a year could receive niraparib following its recommendation by the National Institute for Health and Care Excellence (Nice) for inclusion in the NHS Cancer Drugs Fund (CDF). The Independent
As many as 850 women a year could receive niraparib following its recommendation by the National Institute for Health and Care Excellence (Nice) for inclusion in the NHS Cancer Drugs Fund (CDF). The Independent
No comments:
Post a Comment